Regenxbio (RGNX) Consolidated Net Income (2014 - 2025)

Regenxbio's Consolidated Net Income history runs 12 years deep, the most recent figure standing at -$67.2 million for Q4 2025.

• In Q4 2025, Consolidated Net Income fell 31.01% year-over-year to -$67.2 million; the TTM figure through Dec 2025 stood at -$194.0 million (up 14.66% YoY), while the FY2025 annual figure was -$194.0 million, up 14.59% from the prior year.
• Consolidated Net Income was -$67.2 million for Q4 2025 at Regenxbio, down from -$62.0 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of $294.0 million in Q4 2021 to a low of -$76.7 million in Q1 2022.
• Historically, Consolidated Net Income has averaged -$27.8 million across 5 years, with a median of -$61.9 million in 2023.
• Biggest YoY gain for Consolidated Net Income was 392.34% in 2021; the steepest drop was 764.37% in 2021.
• A 5-year view of Consolidated Net Income shows it stood at $294.0 million in 2021, then fell by 25.04% to $220.4 million in 2022, then tumbled by 128.57% to -$63.0 million in 2023, then grew by 18.58% to -$51.3 million in 2024, then plunged by 31.01% to -$67.2 million in 2025.
• The last three Consolidated Net Income figures came in at -$67.2 million (Q4 2025), -$62.0 million (Q3 2025), and -$70.9 million (Q2 2025), per Business Quant data.